No abstract

Background: Combination of checkpoint inhibitors (CPIs) with anti-angiogenic agents are emerging as potential novel treatment options of hepatocellular carcinoma (HCC).Here we assessed the efficacy and safety of C+A in patients (pts) with advanced HCC.Methods: This phase II study was conducted at 25 study sites in China. Pts with advanced HCC, treatment-naive or failure to sorafenib or donafenib were enrolled. Pts received intravenous C 200 mg every 2 weeks plus A 250 mg qd. The primary endpoint was objective response assessed by independent central review per RECIST v1.1.Results: From Mar 2018 to Jan 2019, 70 pts in first-line setting and 120 pts in secondline setting were enrolled and received treatment of C+A. 168 (88%) of 190 pts were with HBV infection. As of Jan, 2020, median follow-up was 16.7 months and 14.0 months in the first-line and second-line treatment cohort, respectively. The objective response rate (ORR) assessed by independent central review per RECIST v1.1 was 34% and 23%; ORR assessed by independent central review per mRECIST was 46% and 25%; the 12-month overall survival (OS) rate was 75% and 68%, respectively. As of Apr 2020, the 18-month OS rate was 58% in the first-line cohort (table). Overall, 147 (77%) pts had grade 3 treatment-related AEs, with the most common being hypertension (34%), and increased g-GT (12%). Twenty-three (12%) pts discontinued the treatment of either drug due to a treatment-related AE.Conclusions: C+A provided high ORR, durable response with a manageable safety profile in advanced HCC pts. Notably, the remarkable survival benefit might suggest C+A is a promising strategy in advanced HCC pts.Clinical trial identification: NCT03463876.

No abstract

Background: Thymic carcinomas (TC) are remarkably rare aggressive tumors. Due to this, the optimal first-line regimen in patients with advanced TC has not been clarified since the previous studies included a relatively small number of TC patients. The purpose of this study was to evaluate the optimal first-line regimen in patients with advanced TC. Method: We conducted a retrospective study in patients with advanced TC from 2006 to 2015. The primary end point of this study was to evaluate the objective response rate (ORR) and progression free survival (PFS) of different chemotherapy regimens. Age, gender, stage (IVa or IVb), radiation therapy after chemotherapy, resection of primary lesion, different chemotherapy regimens and cycles of chemotherapy were analyzed for significance on PFS. Multivariate Cox model was used to identify significant factors. Result: Sixty-seven patients with stage IV (Masaoka stage) TC were enrolled. Thirty-six patients were treated with paclitaxel-platinum regimen every 3 weeks for a maximum of six cycles. Thirty-one patients were treated with gemcitabine-platinum regimen every 3 weeks for a maximum of six cycles. Resections of primary lesion were performed in fourteen patients before chemotherapy. Thirtythree out of 67 patients were given radiation therapy after chemotherapy. Multivariate analysis demonstrated that different stages (HR ¼ 2.47, P ¼ 0.003), surgical resection (HR ¼ 0.32, P¼ 0.0049) and radiation therapy after chemotherapy (HR ¼ 0.32, P¼ 0.0001) were significantly associated with PFS. The ORR were 31% (11/36) and 29% (9/31) in paclitaxel-platinum regimen group and gemcitabine-platinum regimen group (P¼0.89), respectively. The median PFS, 1-/2-year PFS rates in paclitaxel-platinum regimen group were 7.0 (95% CI 4.0e8.0) months, 26%/6% respectively compared to 12 months (95% CI 11.2e24.0), 48%/24% in gemcitabine-platinum regimen group (P¼0.03). The median PFS, 1-/2year PFS rates were 18.0 (95% CI 12.0e36.0) months/7.3(95% CI

No abstract